Vanguard Portfolio Management
IMVT icon

Vanguard Portfolio Management’s Immunovant IMVT Stock Holding History

Vanguard Portfolio Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151M Buy
3,910,509
+205,604
+6% +$6.26M 0.01% 1348
2026
Q1 		$92M Buy
+3,704,905
New +$95.9M ﹤0.01% 1462

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management's IMVT Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Immunovant (IMVT) stake by 5.5% in Q2 2026, buying an estimated $6.26M and bringing the position to 3,910,509 shares worth $151M. The position accounts for 0.01% of the portfolio, ranked #1348.

Vanguard Portfolio Management first reported a position in IMVT in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Vanguard Portfolio Management held 3,910,509 shares of Immunovant worth $151M as of Q2 2026.
  • Vanguard Portfolio Management bought 205,604 Immunovant shares in Q2 2026, an estimated $6.26M.
  • Immunovant made up 0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1348 holding.
  • Vanguard Portfolio Management first reported a position in Immunovant in Q1 2026 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.